Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391729
Status:
COMPLETED
Last Update Posted:
2011-10-18
First Post:
2006-10-20
Brief Title:
A Dose-Ranging Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-DeficitHyperactivity Disorder ADHD
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-DeficitHyperactivity Disorder ADHD
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 2 mg QD 5 mg QD 15 mg QD 40 mg QD and 40 mg BID to placebo in adults with ADHD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None